This pattern suggests dose-dependent effects on metabolism or gastrointestinal side effects that lead to greater electrolyte and fluid losses
These results come from controlled laboratory and clinical studies and do not guarantee individual outcomes or constitute a claim for the action of a research-grade product
Developing orally administered non-peptide GLP-1 receptor agonists requires sophisticated drug discovery and formulation technologies to achieve adequate oral bioavailability, therapeutic efficacy, and pharmacokinetic performance comparable to injectable GLP-1 therapies
In addition to the glucose-lowering effects associated with GLP-1R agonism, GCGR agonism, via receptors in the liver, may lead to increased energy expenditure [7, 8]
This way, the glucose from the blood is shifted inside the cells, where it is metabolized to produce energy for the body
During adolescence, the body is still growing and going through important hormonal and metabolic changes